Status:
UNKNOWN
Combined Treatment of RFA and Sorafenib on Recurrent HCC
Lead Sponsor:
Southwest Hospital, China
Collaborating Sponsors:
Hunan Province Tumor Hospital
Tang-Du Hospital
Conditions:
HCC
Radiofrequency Ablation
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So t...
Eligibility Criteria
Inclusion
- recurrent HCC after curative resection
- without gender restriction
- age between 18 to 75 years
- The liver function showed no worse than Child-Pugh B
- tumor nodes were less than 5cm and no more than 3 nodules
Exclusion
- Pregnancy patients
- With extrahepatic tumor or lymphnode metastasis
- Tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
430 Patients enrolled
Trial Details
Trial ID
NCT01470495
Start Date
January 1 2015
End Date
December 1 2018
Last Update
March 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of hepatobiliary surgery,southwest hospital
Chongqing, Chongqing Municipality, China, 400038